Ethicon Acquires Rights of Takeda's TachoSil Fibrin Sealant Patch for ~$400M
Shots:
- Takeda tosells its TachoSil Fibrin Sealant Patch along with its ~80 employees to Ethicon for ~ 400M. The transaction is expected to close in H2’19
- Ethicon to acquire the assets and licenses that support the manufacturing- licensing and commercialization of TachoSil while Takeda will retain rights to TachoSil products and supply it to Ethicon
- TachoSil- Fibrin Sealant Patch is a surgical patch designed to control bleeding and generated a revenue of $155M in 2018
Ref: Takeda | Image:Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com